ASH Stock Analysis: Ashland Global Holdings | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 3.359m USD | 12M Return: 38.8% | US0441861046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.9M
EPS Trend: -46.1%
Qual. Beats: 0
Rev. Trend: -95.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ashland Inc. (NYSE: ASH) is a U.S.-based specialty chemicals company that develops and sells additives and specialty ingredients to industrial and consumer-goods manufacturers across North and Latin America, Europe, and Asia Pacific. Founded in 1924 and headquartered in Wilmington, Delaware, the company operates as a B2B ingredients supplier, meaning it does not typically sell branded products to end consumers but rather provides formulation components that other manufacturers incorporate into their own goods. The company is classified within the Materials sector, specifically the Specialty Chemicals sub-industry, and was renamed from Ashland Global Holdings Inc. to Ashland Inc. in August 2022.
The business is organized into four reporting segments. Life Sciences supplies pharmaceutical excipients (controlled-release polymers, disintegrants, tablet coatings, binders), food nutrition ingredients (thickeners, stabilizers, emulsifiers), and agricultural chemicals. Personal Care offers nature-derived and biodegradable ingredients for skin/hair care, oral care, and household cleaning products. Specialty Additives provides rheology modifiers, surfactants, foam-control agents, advanced ceramics for catalytic converters and electronics, and welding alloys. Intermediates produces 1,4-butanediol and derivatives such as n-methylpyrrolidone, which are commodity-like inputs used in downstream chemical manufacturing. End markets served include architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals.
- Pharmaceutical solutions revenue expands on controlled-release polymer demand
- Specialty Additives margins face raw material cost headwinds
- Capital returns accelerate through buybacks and dividend increases
| Net Income: 52.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 5.78 > 1.0 |
| NWC/Revenue: 47.10% < 20% (prev 37.67%; Δ 9.43% < -1%) |
| CFO/TA 0.09 > 3% & CFO 394.0m > Net Income 52.0m |
| Net Debt (1.14b) to EBITDA (390.0m): 2.92 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 29.35% > 18% (prev 25.95%; Δ 3.40% > 0.5%) |
| Asset Turnover: 40.07% > 50% (prev 40.45%; Δ -0.38% > 0%) |
| Interest Coverage Ratio: 3.10 > 6 (EBIT TTM 189.0m / Interest Expense TTM 61.0m) |
| A: 0.19 (Total Current Assets 1.29b - Total Current Liabilities 424.0m) / Total Assets 4.58b |
| B: 0.49 (Retained Earnings 2.26b / Total Assets 4.58b) |
| C: 0.04 (EBIT TTM 189.0m / Avg Total Assets 4.60b) |
| D: 0.69 (Book Value of Equity 1.87b / Total Liabilities 2.71b) |
| Altman-Z'' = 3.86 = AA |
| DSRI: 1.29 (Receivables 256.0m/201.0m, Revenue 1.84b/1.87b) |
| GMI: 0.88 (GM 25.95% / 29.35%) |
| AQI: 0.94 (AQ_t 0.44 / AQ_t-1 0.48) |
| SGI: 0.99 (Revenue 1.84b / 1.87b) |
| TATA: -0.07 (NI 52.0m - CFO 394.0m) / TA 4.58b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of August 23, 2026, the stock is trading at USD 72.66 with a total of 334,531 shares traded. Over the past week, the price has changed by -1.42%, over one month by +6.06%, over three months by +30.09% and over the past year by +38.83%.
Current recommended Stop Loss: 69.90 (which is 3.8% or 1.2 ATR below the current price).
Ashland Global Holdings has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy ASH.
- StrongBuy: 6
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80.2 | 10.3% |
P/E Trailing = 47.9412
P/E Forward = 16.835
P/S = 1.8235
P/B = 1.8464
P/EG = 1.226
Revenue TTM = 1.84b USD
EBIT TTM = 189.0m USD
EBITDA TTM = 390.0m USD
Long Term Debt = 1.37b USD (from longTermDebt, last quarter)
Short Term Debt = 18.0m USD (from shortTermDebt, last quarter)
Debt = 1.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 102.0m
Net Debt = 1.14b USD (calculated: Debt 1.58b - CCE 440.0m)
Enterprise Value = 4.50b USD (3.36b + Debt 1.58b - CCE 440.0m)
Interest Coverage Ratio = 3.10 (Ebit TTM 189.0m / Interest Expense TTM 61.0m)
EV/FCF = 13.92x (Enterprise Value 4.50b / FCF TTM 323.0m)
FCF Yield = 7.18% (FCF TTM 323.0m / Enterprise Value 4.50b)
FCF Margin = 17.53% (FCF TTM 323.0m / Revenue TTM 1.84b)
Net Margin = 2.82% (Net Income TTM 52.0m / Revenue TTM 1.84b)
Gross Margin = 29.35% ((Revenue TTM 1.84b - Cost of Revenue TTM 1.30b) / Revenue TTM)
Gross Margin QoQ = 31.19% (prev 30.50%)
Tobins Q-Ratio = 0.98 (Enterprise Value 4.50b / Total Assets 4.58b)
Interest Expense / Debt = 3.87% (Interest Expense 61.0m / Debt 1.58b)
Taxrate = 40.0% (50.0m / 125.0m)
NOPAT = 113.4m (EBIT 189.0m * (1 - 40.00%))
Current Ratio = 3.05 (Total Current Assets 1.29b / Total Current Liabilities 424.0m)
Debt / Equity = 0.84 (Debt 1.58b / totalStockholderEquity, last quarter 1.87b)
Debt / EBITDA = 2.92 (Net Debt 1.14b / EBITDA 390.0m)
Debt / FCF = 3.52 (Net Debt 1.14b / FCF TTM 323.0m)
Total Stockholder Equity = 1.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.13% (Net Income 52.0m / Total Assets 4.58b)
RoE = 2.77% (Net Income TTM 52.0m / Total Stockholder Equity 1.88b)
RoCE = 5.82% (EBIT 189.0m / Capital Employed (Equity 1.88b + L.T.Debt 1.37b))
RoIC = 2.78% (NOPAT 113.4m / Invested Capital 4.08b)
WACC = 6.59% (E(3.36b)/V(4.94b) * Re(8.60%) + D(1.58b)/V(4.94b) * Rd(3.87%) * (1-Tc(0.40)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.83 | Cagr: -4.48%
[DCF] Terminal Value 77.97% ; FCFF base≈217.4m ; Y1≈249.2m ; Y5≈366.8m
[DCF] Fair Price = 95.68 (EV 5.52b - Net Debt 1.14b = Equity 4.38b / Shares 45.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -46.05 | EPS CAGR: -5.42% | SUE: -0.10 | # QB: 0
Revenue Correlation: -95.05 | Revenue CAGR: -7.59% | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-12-31): EPS=0.32 | Chg30d=-7.15% | Revisions=-25% | Analysts=4
EPS current Year (2026-09-30): EPS=3.55 | Chg30d=-0.51% | Revisions=-44% | GrowthEPS=+4.9% | GrowthRev=+2.2%
EPS next Year (2027-09-30): EPS=4.31 | Chg30d=+1.40% | Revisions=-38% | GrowthEPS=+21.7% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -53% (up=2, down=10)